• Privacy Policy
  • Terms & Conditions
Top Stocks Insider
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Top Stocks Insider
No Result
View All Result
Home News

Stanley Goldfarb on Taking CRT Out of the Exam Room

by
May 3, 2022
in News
0
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Our guest is Dr. Stanley Goldfarb, author of the recently-released Take Two Aspirins and Call Me By My Pronouns, a book that details the intrusion of critical race theory and identity politics into medical education and medical practice. He is a former Associate Dean for Curriculum at the University of Pennsylvania Perelman School of Medicine and returns to the show to discuss his book and the new organization that he is leading to push back against the new trend.

SHOW NOTES​

Stanley Goldfarb: Twitter

Do No Harm

Related Episode: Ep. 102 Curriculum Subverted: An Academic Leader Pushes Back Against Woke Medicine (with Stanley Goldfarb)

Related Episode: Ep. 140 Amy Wax on Wokeness in Medicine

Related Episode: Ep. 149 James Lindsay: Critical Race Theory, Post-Modernism, and Medicine

Watch the episode on the Accad & Koka Report YouTube channel

Previous Post

Why Social Issues Dominate

Next Post

The Fed Gets It Wrong on Money Velocity, Too

Next Post
The Fed Gets It Wrong on Money Velocity, Too

The Fed Gets It Wrong on Money Velocity, Too

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Disclaimer: TopStocksInsider.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2024 TopStocksInsider. All Rights Reserved.

    No Result
    View All Result
    • News
    • Economy
    • Editor’s Pick
    • Investing
    • Stock

    Copyright © 2024 TopStocksInsider. All Rights Reserved.